Nasal COVID vaccine discovered by?

NORCET 3 - 2022 (Shift-2)

Pharmacology

Easy

Appeared in: NORCET 3 - 2022 (Shift-2)

Explanation

Bharat Biotech, a biotechnology company based in Hyderabad, India, developed the country's first intranasal COVID-19 vaccine.
The vaccine, branded as iNCOVACC (codename BBV154), was developed in partnership with Washington University School of Medicine in St. Louis, USA.
It is a needle-free vaccine administered as nasal drops, designed to elicit a strong immune response in the nasal mucosa, the entry point for the SARS-CoV-2 virus.
This approach aims to create 'mucosal immunity', which can potentially block infection and reduce transmission more effectively than intramuscular shots.

Option B: The Serum Institute of India (SII) was the primary manufacturer of the Covishield vaccine in India, which is an intramuscular injection, not a nasal vaccine.
Option C: The National Institute of Virology (NIV), Pune, is a premier research institute. While it played a crucial role in the pandemic by isolating the SARS-CoV-2 virus strain, which was used to develop Covaxin by Bharat Biotech, it was not the primary developer of the commercial nasal vaccine.
Option D: AstraZeneca, a British-Swedish pharmaceutical company, co-developed the Vaxzevria vaccine with the University of Oxford. This vaccine is administered intramuscularly. It was licensed to the Serum Institute of India for production under the brand name Covishield.

Visual 1: Infographic - A comparison chart showing the mechanism of action for an intramuscular vaccine versus a nasal vaccine, highlighting how nasal vaccines create mucosal immunity (IgA) in the respiratory tract.
Visual 2: Diagram - A simple illustration showing the administration of a nasal vaccine as drops into the nostrils.

Clinical Relevance

Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain COVID-19 Vaccine Development in India as background academic context rather than a clinical decision trigger.
Nasal vaccines represent a significant advancement in immunization strategy, particularly for respiratory pathogens.
Nurses play a key role in educating patients about new vaccine types, explaining the benefits of mucosal immunity, and demonstrating the correct administration technique for nasal drops.
What if? - If a patient has a severe nasal congestion or a deviated septum, the absorption and effectiveness of a nasal vaccine might be compromised. In such cases, an intramuscular vaccine might be a more reliable alternative, and the nurse should consult the prescribing physician.

How to Approach the Question

First, identify the key terms in the question: 'Nasal COVID vaccine' and 'discovered by'. This is a factual recall question about a specific medical product.
Recall or look up the major players in India's COVID-19 vaccine development.
Associate each organization with its primary vaccine product: Bharat Biotech with Covaxin and the nasal vaccine (iNCOVACC), and Serum Institute with Covishield.
Differentiate between the developer (AstraZeneca) and the Indian manufacturer (Serum Institute) for Covishield.
Recognize the role of research bodies like NIV as collaborators or foundational researchers, not typically the final commercial developers.
Based on these associations, select the company directly linked to the development of the nasal vaccine.

Concept Tested & Keywords

QEah9yKDyBANKCIQtdGzrN